CyFi: A phase I study exploring the role of cMET pathway inhibition with ficlatuzumab (Fi) combined with high-dose cytarabine (Cy) in patients with high risk relapsed or refractory acute myeloid leukemia (AML).

Victoria Wang,Gabriel N. Mannis,Rebecca L. Olin,Aaron C Logan,Thomas G. Martin,Lloyd E. Damon,Danielle Kilayko,Pamela N. Munster,Charalambos Andreadis

CyFi: A phase I study exploring the role of cMET pathway inhibition with ficlatuzumab (Fi) combined with high-dose cytarabine (Cy) in patients with high risk relapsed or refractory acute myeloid leukemia (AML).

2017

Victoria Wang
Gabriel N. Mannis
Rebecca L. Olin
Aaron C Logan
Thomas G. Martin
Lloyd E. Damon
Danielle Kilayko
Pamela N. Munster
Charalambos Andreadis

7040Background: Pts with AML who are refractory to induction therapy or relapse within 1 year have poor outcomes. Elevated serum HGF level is an adverse prognostic factor in AML (Verstovsek, et al....

Keywords:

Ficlatuzumab
Myeloid leukemia
Cancer research
Physical therapy
Medicine
Cytarabine
Refractory
in patient
Oncology
Internal medicine
phase i study
induction therapy
high dose cytarabine
Pathology
elevated serum

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations